HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
ConditionPancreatic Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorRuijin Hospital
About this trial
To evaluate the safety and efficacy of HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Eligibility criteria
Qualifiers
Age: ≥18 and ≤80 years old, male or female;
Pathologically or cytologically confirmed ductal adenocarcinoma of the pancreas; and subjects must have at least one measurable lesion as defined by RECIST v1.1;
Imaging evaluation met the NCCN guidelines definition of resectable pancreatic cancer (including high-risk resectable) and borderline resectable pancreatic cancer.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
Disqualifiers
Previously received any anti-tumor therapy;
the presence of distant metastatic lesions diagnosed by imaging;
Known hypersensitivity to the study drug or any of its components;
previous or concurrent other malignant tumors;
Trial design
Treatments tested in this trial
- HRS-4642+AG
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Ruijin Hospital
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborator
Source ClinicalTrials.gov